CAR T-cell-specific assessment criteria should be defined in pharmacovigilance activities and specific molecular test methods should be established. These steps will further increase patient safety.

CAR T-cell therapies have established themselves as a frequently very successful and overall promising treatment option for various blood cancers for which no other effective therapies are available.

The global pharmacovigilance market, valued at USD 6.87 billion in 2023, is projected to expand at a CAGR of 13%, reaching ...

Register Now for the Pharmacovigilance USA Conference 2025: Empowering Safety Through Innovation And Real-World Evidence: Shaping The Future Of Pharmacovigilance (Boston, US - July 22-23, 2025) - ...